Navigation Links
Global Intravenous (IV) Iron Drugs Industry
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Intravenous (IV) Iron Drugs Industry

http://www.reportlinker.com/p0305172/Global-Intravenous-IV-Iron-Drugs-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 18 companies including many key and niche players such as AMAG Pharmaceuticals, Inc., Fresenius Medical Care AG & Co. KGaA, Galenica Ltd., Vifor Pharma Ltd., Luitpold Pharmaceuticals, Inc., American Regent, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., Sanofi-Aventis U.S. LLC, Syner-Med (Pharmaceutical Products) Ltd., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

INTRAVENOUS (IV) IRON DRUGS MCP-6464

A GLOBAL MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1

A Quick Primer II-1

Current and Future Analysis II-1

United States - The Largest Market for IV Iron Drugs II-1

Europe and Rest of World - High Potential Markets II-2

Noteworthy Trends in the IV Iron Drug Market II-2

No Impact of Recession on Intravenous Iron Market II-2

Dialysis Clinics are Major Clients for IV Iron Supplements II-2

Global Iron Supplement Market II-2

Table 1: Global Intravenous (IV) Iron Market (2006):

Percentage Breakdown of Value Sales for Intravenous Iron Drug

Type - Non Generics and Generics II-3

Table 2: Leading Players in the Global Intravenous (IV) Iron

Market (2006): Percentage Breakdown of Value Sales for Vifor,

Sanofi-Aventis, Pharmacosmos, and Others (including Generics)

(includes corresponding Graph/Chart) II-3

Vifor Pharma - Dominates IV Iron Drugs Market II-3

2. OVERVIEW OF INTRAVENOUS (IV) IRON DRUGS II-4

Significance of Iron in Human Body II-4

Intravenous Therapy II-4

Iron-Deficiency Anemia II-4

People with High Susceptibility to Anemia II-4

Older Adults & the Elderly II-5

Cancer Patients II-5

Women of Child-bearing Age II-5

Chronic Kidney Disease Patients II-5

HIV/AIDS Patients II-5

People with Inflammatory Bowel Disease II-5

Diabetics II-6

People with Heart Disease II-6

Critically Ill Patients II-6

Infants II-6

People with Other Diseases II-6

Table 3: Intravenous (IV) Iron Drugs Market (2009):

Prevalence of Iron Deficiency Disease (IDA) by Risk Groups-

Pregnant Women, Children (1-2 years), Women (12-49

years), Women (50+ years), and Men (12+ years) (includes

corresponding Graph/Chart) II-6

Treatment for Iron Deficiency Anemia II-7

Iron Requirement in Chronic Kidney Disease II-7

Classification of Iron Deficiency in CKD II-7

Treating Iron Deficiency in CKD Patients II-7

Side Effects of Iron Supplementation in CKD II-8

Methods of Restoring Iron II-8

Oral Iron Therapy II-9

IV Iron-Infusion Therapy II-9

Intravenous (IV) Iron II-9

Conditions for Receiving Iron Injections II-10

Injection Procedure II-11

Categories of Iron Injections II-11

Ferumoxytol II-11

Iron Dextran II-12

Carbohydrate Iron II-12

Suitability of IV Iron Preparation II-12

Suitability of Regimen II-13

Management of Iron Doses II-13

Effectiveness of Iron Injection II-14

Requirement of Test Dose II-14

Side Effects of Iron Injections II-15

Iron Therapy: Caution II-15

Relevance of Iron Infusion Time II-15

Iron Overdose II-15

Iron-Out-of-Balance Therapies II-16

Blood Donation II-16

Therapeutic Phlebotomy II-16

Red Cell Apheresis II-16

Iron Chelation Therapy II-16

Iron-Chelating Drugs II-17

Desferrioxamine or Desferal II-17

Deferiprone or Ferriprox II-17

Conditions for Undergoing Iron Chelation Therapy II-17

Kinds of Chelation Therapy II-18

Side Effects Caused by IV Iron Chelation II-18

Conclusion II-19

3. SELECT IV IRON DRUGS PRESCRIBED FOR IRON DEFICIENCY II-20

Iron Sucrose (Venofer®) II-20

Iron dextran (InFed®, Dexferrum®) II-20

Sodium Ferric Gluconate (Ferrlecit®) II-21

Ferumoxytol (FerahemeTM) II-21

Ferric Carboxymaltose (Ferinject®, Injectafer®) II-22

4. SOLUBLE FERRIC PYROPHOSPHATE (SFP): A PIPELINE DRUG II-23

5. CLINICAL TRIALS II-24

Rockwell Medical Technologies Presents Positive Clinical Data

on Phase IIb Study of SFP II-24

FAIR-HF Study Meets Primary Endpoints in Treating Iron

Deficiency and Chronic Heart Failure II-25

6. PRODUCT LAUNCHES/APPROVALS II-26

AMAG Pharmaceuticals Launches Feraheme™ in the US II-26

Feraheme™ Receives FDA Approval for Intravenous Iron Therapy

in Adult CKD Patients II-26

Syner-Med Unveils Ferinject® in the UK II-27

Galencia Receives Approval in EU for Ferinject II-27

7. RECENT INDUSTRY ACTIVITY II-28

AMAG Pharmaceuticals Inks Agreement with Takeda Pharmaceutical

Company for Feraheme® II-28

Pharmacosmos Bags Marketing Authorizations for Monofer® II-28

Pharmacosmos Launches New Subsidiary II-28

Watson Pharmaceuticals Inks License Agreement with GeneraMedix II-29

Dabur Pharma Gets A New Name II-29

AMAG Pharmaceuticals Inks Agreement with 3SBio II-29

Fresenius Kabi Acquires Dabur Pharma II-30

Fresenius Medical Care Inks License Agreement with Luitpold

Pharmaceuticals and American Regent II-30

Fresenius Medical Care Inks Licensing Agreements for IV Iron

Products II-31

8. FOCUS ON SELECT GLOBAL PLAYERS II-32

AMAG Pharmaceuticals, Inc. (US) II-32

Fresenius Medical Care AG & Co. KGaA (Germany) II-32

Galenica Ltd. (Switzerland) II-32

Vifor Pharma Ltd. (Switzerland) II-32

Luitpold Pharmaceuticals, Inc. (US) II-33

American Regent, Inc. (US) II-33

Pharmacosmos A/S (Denmark) II-34

Rockwell Medical Technologies, Inc. (US) II-34

Sanofi-Aventis U.S. LLC (US) II-34

Syner-Med (Pharmaceutical Products) Ltd. (UK) II-34

Watson Pharmaceuticals, Inc. (US) II-35

9. GLOBAL MARKET PERSPECTIVE II-36

Table 4: World Recent Past, Current and Future Analysis for

Intravenous (IV) Iron Drugs by Geographic Region - US, Europe,

and Rest of World Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2007 through 2015

(includes corresponding Graph/Chart) II-36

Table 5: World Historic Review for Intravenous (IV) Iron Drugs

by Geographic Region - US, Europe, and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2001 through 2006 (includes corresponding

Graph/Chart) II-37

Table 6: World 13-Year Perspective for Intravenous (IV) Iron

Drugs by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Europe, and Rest of World Markets for Years

2003, 2009 and 2015 (includes corresponding Graph/Chart) II-38

III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Outlook III-1

CKD Revs up Growth in the US Market for IV Iron III-1

Regulatory Environment to Affect IV Iron Market in Future III-1

Noteworthy Trend in IV Iron Utilization in the US III-1

Competitive Scenario III-2

Table 7: US IV Iron Therapy Replacement Market (2009):

Percentage Breakdown of Volume Sales by Products for

Venofer, Ferrlecit, INFeD, Dexferrum and Feraheme (includes

corresponding Graph/Chart) III-2

Table 8: US IV Iron Therapy Replacement Market (2008):

Percentage Breakdown of Value Sales by Products for

Venofer, Ferrlecit, INFeD, and Dexferrum (includes

corresponding Graph/Chart) III-2

Product Launches/Approvals III-3

Strategic Corporate Developments III-4

Select Players III-5

B.Market Analytics III-7

Table 9: US Recent Past, Current and Future Analysis for

Intravenous (IV) Iron Drugs with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) III-7

Table 10: US Historic Review for Intravenous (IV) Iron Drugs

with Annual Sales Figures in US$ Million for Years 2001

through 2006 (includes corresponding Graph/Chart) III-8

2. EUROPE III-9

A.Market Analysis III-9

Outlook III-9

Product Launches/ Approvals III-9

Strategic Corporate Developments III-9

Select Players III-11

B.Market Analytics III-13

Table 11: European Recent Past, Current and Future Analysis

for Intravenous (IV) Iron Drugs with Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-13

Table 12: European Historic Review for Intravenous (IV) Iron

Drugs with Annual Sales Figures in US$ Million for Years

2001 through 2006 (includes corresponding Graph/Chart) III-13

3. REST OF WORLD III-14

A.Market Analysis III-14

Outlook III-14

Strategic Corporate Developments III-14

B.Market Analytics III-15

Table 13: Rest of World Recent Past, Current and Future

Analysis for Intravenous (IV) Iron Drugs with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) III-15

Table 14: Rest of World Historic Review for Intravenous (IV)

Iron Drugs with Annual Sales Figures in US$ Million for

Years 2001 through 2006 (includes corresponding Graph/Chart) III-15

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 18 (including Divisions/Subsidiaries - 24)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 9

Japan 1

Europe 8

France 1

Germany 2

The United Kingdom 2

Rest of Europe 3

Asia-Pacific (Excluding Japan) 6

------------------------------------------

To order this report:

Drug Delivery Technology Industry: Global Intravenous (IV) Iron Drugs Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
3. Reportlinker Adds Renal Dialysis Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
4. Reportlinker Adds Cardiovascular Monitoring and Diagnostic Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
5. Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
6. VisiInc PLC and MMRGlobal Announce Agreement to Launch MyMedicalRecords Australia
7. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
8. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
9. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Derycz Scientific Hires AstraZeneca Executive to Drive Global Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located at ... Top Patient Rated Henderson Dentist by Find Local Doctors earlier this year. ... dentists who have earned high ratings and superior patient reviews from multiple credible sources. ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... Minneapolis MN (PRWEB) , ... February 23, 2017 , ... ... it is sending an expert sit stand solutions representative to the Minneapolis Home and ... 5. Location for the event that is garnering national attention is the Minneapolis Convention ...
(Date:2/22/2017)... FL (PRWEB) , ... February 22, 2017 , ... Gevir, ... from deer antler velvet, announced its products are coming soon to Amazon.com, the world’s ... and Shelley Thomson as a means to develop an effective natural treatment for Shelley’s ...
(Date:2/22/2017)... ... ... South Bend’s Lunkerville, the award-winning TV series that catches real people with ... a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through kayak ... Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the New ...
Breaking Medicine News(10 mins):